Correlation Between Arrow Financial and Centessa Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arrow Financial and Centessa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arrow Financial and Centessa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arrow Financial and Centessa Pharmaceuticals PLC, you can compare the effects of market volatilities on Arrow Financial and Centessa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arrow Financial with a short position of Centessa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arrow Financial and Centessa Pharmaceuticals.

Diversification Opportunities for Arrow Financial and Centessa Pharmaceuticals

0.68
  Correlation Coefficient

Poor diversification

The 3 months correlation between Arrow and Centessa is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Arrow Financial and Centessa Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Centessa Pharmaceuticals and Arrow Financial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arrow Financial are associated (or correlated) with Centessa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Centessa Pharmaceuticals has no effect on the direction of Arrow Financial i.e., Arrow Financial and Centessa Pharmaceuticals go up and down completely randomly.

Pair Corralation between Arrow Financial and Centessa Pharmaceuticals

Given the investment horizon of 90 days Arrow Financial is expected to generate 12.11 times less return on investment than Centessa Pharmaceuticals. But when comparing it to its historical volatility, Arrow Financial is 1.97 times less risky than Centessa Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Centessa Pharmaceuticals PLC is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  328.00  in Centessa Pharmaceuticals PLC on September 13, 2024 and sell it today you would earn a total of  1,390  from holding Centessa Pharmaceuticals PLC or generate 423.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Arrow Financial  vs.  Centessa Pharmaceuticals PLC

 Performance 
       Timeline  
Arrow Financial 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Arrow Financial are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, Arrow Financial may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Centessa Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Centessa Pharmaceuticals PLC are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Centessa Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Arrow Financial and Centessa Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arrow Financial and Centessa Pharmaceuticals

The main advantage of trading using opposite Arrow Financial and Centessa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arrow Financial position performs unexpectedly, Centessa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Centessa Pharmaceuticals will offset losses from the drop in Centessa Pharmaceuticals' long position.
The idea behind Arrow Financial and Centessa Pharmaceuticals PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements